Cart summary

You have no items in your shopping cart.

Letrozole

SKU: orb1226953

Description

Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. (In Vitro):Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells(In Vivo):Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats.

Images & Validation

Key Properties

CAS Number112809-51-5
MW285.3
Purity>98% (HPLC)
FormulaC17H11N5
SMILESN#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N3N=CN=C3)C=C1
TargetAromatase
SolubilityDMSO: 57 mg/mL (199.78 mM)

Bioactivity

In Vivo
Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats. Animal model: Adult female rats bearing mammary tumors. Dosage: 3, 10, 30, 100, 300 μg/kg. Administration: Oral gavage once daily for 6 weeks. Result: Induced complete regression of mammary tumors, with an ED50 of 10-30 μg/kg/day.
In Vitro
Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner. Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation. Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells. Cell Viability Assay Cell line: MCF-7 cells. Concentration: 0.1, 1, 10, 100 nM Incubation time: 24, 48, 96 hours. Result: Inhibited cells growth in a dose- and time-dependent manner.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

CGS 20267

Similar Products

  • Bis(4-cyanophenyl)methanol [orb1310521]

    100.00%

    134521-16-7

    234.25

    C15H10N2O

    1 ml x 10 mM (in DMSO), 200 mg
  • Letrozole related compound B [orb1705485]

    112809-52-6

    285.30

    C17H11N5

    25 mg, 100 mg
  • Letrozole [orb1308084]

    99.84% (May vary between batches)

    112809-51-5

    285.3

    C17H11N5

    25 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Letrozole (orb1226953)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

25 mg
$ 70.00
50 mg
$ 90.00
100 mg
$ 100.00
200 mg
$ 110.00
500 mg
$ 120.00